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ABSTRACT 
Objective: To review the risk in pharmaceutical industries and the risk management process and tools. There is risk always in anything we do. All the industries on this globe 
perform actions that involve risks; risk is only dangerous when there is no anticipation to manage it. Risks if assessed and controlled properly will benefit the industries against 
the fall and makes stronger. Risk should not be assessed as bad, but should assess as an opportunity for making things resilient by proper management. Risk management 
can benefit industries from disasters either natural or human. The impact of the risk should be assessed in order to plan alternatives and minimize the effect of the impact. 
Risk in pharmaceutical industry is  very high because it involves research, money and health. The impact is severe and the probability of the risk is more often in 
pharmaceutical industry. A risk management plans and control measures will help the companies to do better at the time of uncertainties and create positive opportunities to 
turn those risks into benefits which maximize quality. Materials and Methods: The information was collected and compiled from scientific literature present in different 
databases and articles, books. Results: The risk management process and tools helps to minimize the risk and its effects. Conclusion: The risk management is at the core of 
any organization. Risk management should be part of organization culture. The risk management is a wise investment if properly processed. 
Key words: Risk, Management, ICH Q9, uncertainty, Pharmaceutical Risks. 
INTRODUCTION 
The word Risk has been used since 1621 as risqué and later it 
has  been  spelled  as  Risk  since  1655.  What  is  risk?  Risk  as 
various  definitions,  as  per  The ISO  31000 (2009)  /ISO  Guide 
73:2002 definition of risk is the 'effect of uncertainty on objectives'. 
Effect  
An effect can change or alter the result, goal, objective we need or 
expected. It might be positive or negative. 
Objective  
An  objective  is  varied  or  differed.  It  can  be  financially,  health, 
environment, production, process, organization, profits and sales 
objectives etc.  
Uncertainty 
Uncertainty  is  the state  at  which  there  is  a  partial  or complete 
absence of information related to knowledge or understanding an 
event, its consequence, or likelihood. 
That means  we  do  not  have  clue  about  an  event  (a  particular 
happening, occasion, occurrence) and what will be the outcome of 
that, a positive or negative result. Risk is always associated with 
things  that  are  uncertain.  There  can  be  lot  of  examples  to 
understand uncertainty, a sudden fire broke out from an industry, 
or loss of valuable resources in an accident, a natural calamities. 
All  these  are  uncertain  things  where  we  got  no  idea  when  it 
happens. 
But most common definition of the word "risk" is possibility 
of loss or injury. 
Risks can be positive too, positive risks are risks that result in 
good things happening; sometimes called opportunities. 
An organization can be of any type large, medium, small, profit 
and non–profit organizations; they all have certain objectives and 
goals.  There  is  no  organization  is  devoid  of  goal.  While  every 
organization when striving to reach their goals there are lots of 
factors that cause the deviation, or delay in reaching the desired 
goals. 
Risk management in Pharmaceuticals [2]  
Risk is associated in every single aspect in pharmaceuticals from 
development of a molecule to its way to the customer. We should 
be aware of important risks associated in Pharma.  
  Regulatory  risks  –  The  stringent  laws  and  rules  made  by 
regulatory bodies which change often, are very hard to keep 
up by the companies, which involves a lot of efforts.  
  Human risks - Human errors, risks involved in shortage of 
skills, l oss of personnel. 
  Financial risk – These risks involve in financial transactions, 
loans, uncertainty of a return, interests rate etc... 
  Foreign exchange risk – Risks of exchange rates, economic 
conflict between countries. 
  Market risk – This might be due to risks from stock, interest 
rates,  commodity  rates,  even  foreign  exchange  rates  also 
affect the market. 
  Political risk  – This risks associated are due to change of 
governments, leaders. 
  Area risk – Location of the business running, support of the 
public nearby. 
  Natural  hazard  risk  –  Risks  because  of  natural  calamities 
which is danger for every type of business. 
  External threats – Risks like loss of value due to competitors, 
substitutes in the market. 
  Security Risk of security breach, loss of documents, data or 
any other value information. It might be either due to external 
or internal persons. 
These are the risks mostly associated with Pharma industry. But 
pharmaceutical  industries  involve  in  making  a  product  which  is 
used or consumed by living creatures which is called as drug. So 
making  of  a  drug  is  a  complex  process  from  research  & 
development to its way out into the market. It is a risky journey. 
The uncertainty of risk associated is very high. To understand the 
various  risks  involved  primarily  the  drug  life  cycle  should  be 
understood. 
DRUG LIFE CYCLE 
Discovery and Research [3]  
The  need  to  discover  starts  by  understanding  the  basic  of  a 
disease, how it occurs and its effect on the body from cellular level 
to genetic level, every aspect should be clear. Then every known 
molecule  or  discovered  molecule  has  been  targeted  to  interact 
with  the  target  and  its  effect  of  the  molecule  on  the  particular 
target will be known. The molecule may either work or may not on 
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Drug Development  
It  involves  developing  the  lead  molecule  or  the  most  potent 
structure is constructed which is effective. After developing a lead 
molecule  testing  is  done  which  is  very  much  required  by 
regulatory bodies in cellular level that is in cells (in vitro) and in 
animals (in vivo). By this the effects or the action of the drug is 
well known. A drug molecule is subjected to clinical trials which 
help to find out valuable information of the molecule or drug those 
are  safety,  efficacy,  toxicity  and  various  studies  of 
pharmacodynamics  and  pharmacokinetic  characteristics.  These 
clinical trials involve testing drug on human volunteers. 
Regulatory Review and Approval  
After  the  clinical  trials,  the  data  or  the  results  obtained  in  the 
clinical  trials  should  be  submitted  to  authorities  e.g.  FDA  and 
national authorities. These authorities after a thorough inspection 
of the clinical data, safety, and efficacy of the drug molecule will 
then give approval to drug manufacturing.  
Production and marketing  
After the approval by the regulatory authorities the drug can be 
manufactured in large scale and marketed which involves time, 
money  and  efforts  for  developing  the  quality  to  the  maximum. 
Later the post marketing surveillance is conducted which is called 
as phase 4 clinical trial. To know the effect of the drug after it has 
been  marketed  and  used  by the  patients  over  large  population 
and various regions.  
Pharmaceutical world is growing rapidly and market is growing in 
terms of value and volume. The norms of the regulatory bodies 
make new challenges to the industry because laws in the pharma 
made by regulatory bodies are more stringent.  
The uncertainty of risk levels in the research is high because we 
do not know whether the drug molecule is successful or not. It 
involves lot of time, money and has more prone to failure. The 
drug research is complex process and companies which are huge 
can face these problems than the small ones which are new and 
financially unstable with less experience in the research.  
Patent is very much required for a drug in development and to get 
the  rights  to  sell  the  developed  drug  for  a  time  period.  The 
company  which  has  a  patent  on  the  drug  molecule  enjoys  the 
monopoly pricing for a period of twenty years. 
There is no need for a company to invent or formulate a new drug; 
it may also enter the generic market in which the drug prices of a 
generic drug are 30-90% less than the branded drugs. But the 
generic drugs can be manufactured only after a time period i.e. if 
a patent expires of the branded drug or filing an ANDA application 
which  involves  stringent  regulations,  and  time  driven  actions  to 
make and market the generic drugs. 
After  the  research  activities  and  developing  a  molecule  which 
shows  the  sign  of  action  are  selected  and  its  effect  will  be 
recorded or known by performing clinical trials. The trials involves 
on animals in laboratory and then on humans later. The clinical 
trial involves four phases. 
Phase  1  It  involves  testing  the drug  on  20  –  80  volunteers  to 
check the safety of the drug in the given dose level. If there are 
any abnormalities or unacceptable reactions that occur then the 
drug will be terminated. This means after the research of the drug 
for years investing time, money, and efforts if the drug molecule is 
working  negatively  than  the  required  action  it  has  been 
terminated, so the level of risk is high. 
Phase 2 It involves testing the drug on more humans counting in 
hundreds (100 – 300). In this the drug efficacy along with effective 
dosage and administration frequency are analysed, if the results 
are not satisfactory, the drug is taken back to further development. 
Phase 3 Thousands of patients are involved in phase 3, about 
300 – 3000 patients are selected and testing is done. This phase 
is most expensive and time taking. Efficacy of the drug and drug-
drug interactions, side effects, toxicity, plant design are also been 
studied, and every aspect should be documented and statistical 
data must be presented to regulatory bodies. At this phase of drug 
trials any unwanted action by the drug or any misrepresentation of 
data might put the company in trouble.  
Phase  4  It  is  called  as  post  marketing  surveillance  i.e.  after 
approval  of  the  drug  to  enter  into  the  market.  The  safety 
surveillance is done that is called as pharmacovigilance. In which 
further  drug  –  drug  interactions,  actions  of  drugs  on  pregnant 
women  and  long  term  adverse effects  on  large  population  and 
over the long time are collected. If there are any adverse reactions 
occurred over long time then the drug manufacturing is stopped 
and all the investment made is a loss. 
The entire process from drug research to this point takes about 12 
– 14 years and involves billions of us dollar. (Costing over 1 billion 
U.S $). 
Out of approximately 5000 screened compounds only 250 goes 
for preclinical testing and 5 move to clinical testing and only one 
compound gets approval to manufacture and market. 
The risk involved in clinical trials is the highest because humans 
are involved and lots of works (studies) are conducted and the 
probability  of  uncertainty  is  high.  The  molecule  when  shows 
undesired  effect  the  whole  project  of  drug  development  is 
terminated. 
Then  the  manufacturing  of  the  drug  at  industry  scale  is  done, 
which  involves  the  suppliers,  raw  materials,  equipment  - 
machines,  technology,  employees,  teams,  managers, 
shareholders  and  huge  money  investment.  All  these  are  called 
internal  and  external  stake  holders.  External  also  involves 
consumers, public, political systems, etc...  
So the personnel involved in pharma drug manufacturing should 
be  skilled  and  qualified.  The  equipment  should  have  required 
standards so that the quality of the product is never reduced. The 
quality is one of the most important assets and it is very much 
required because the drug designed has been administered by a 
human and any deteriorated quality will affect the people’s health. 
[4]
 
Even  the  large  companies  may  have  lot  of  rigorous  research 
going but will have very few products in the market which should 
cover the expenses of the research going and manufacturing of 
the current products. 
Fraud  is  the  most  dangerous  risk,  which  involves  either  own 
personnel or external person involving in stealing the data or the 
formulae and other important information which makes huge loss 
of efforts made and time spent. 
The  marketing  and  sales  is  a  high  priority  in  Pharma,  which 
involves  post  surveillance  and  making  sales  effective  by  sales 
force, who focus on primarily the doctor and the pharmacists. 
These sales people who are known as Pharma marketers require 
scientific  knowledge  about  the  product  with  more  of 
communication and interpersonal skills because they need to sell 
the product or should make a doctor to prescribe it to a patient. 
Risk involved here is skilled and proper knowledgeable personnel 
should be employed and trained well, if not competitors product 
might be prescribed by the doctor and loss of sales may occur, a 
proper relationship should be maintained with doctor. 
As  in  every  industry  the  risk  of  natural  calamities  is  often,  the 
Pharma industry is also prone to it when proper measures are not 
taken against fire, earthquake, floods, rains, etc...  
Always a contingency plan should be present and made with past 
experiences and expert references. 
Risk management plan  
A  risk  management  plan  helps  to  find  out  the  possible  risks 
involved in every aspect of research, development, manufacture 
and marketing. 
  What are the risks? 
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  Who is at risk? 
  What might be the loss due to the risk? 
  Are they avoidable? 
So  first  the  root  cause  of  the  risk  should  be  known,  then  the 
probability of occurrence and its impact is figured and this helps to 
reduce the loss level to acceptable level.  
The Risk Management Strategy gives an idea in which risks and 
issues  will  be  figured.  How  risks  and  issues  will  be  raised, 
analysed, reviewed, communicated, and escalated. 
Risk management process: [5, 6] 
The process of Risk management involves four phases. 
  Mitigation 
  Preparedness 
  Response 
  Recovery 
Mitigation 
Mitigation efforts attempt to prevent hazards from developing into 
disasters, or to reduce the adverse impact of disasters when they 
occur. The mitigation phase differs from the other phases because 
it focuses on the long-term measures for reducing or eliminating 
risk.  The  implementation  of  mitigation  strategies  can  also  be 
considered  a  part  of  the  recovery  process  if  applied  after  a 
disaster  occurs.  However,  even  if  applied  as  part  of  recovery 
efforts,  actions  that  reduce  or  eliminate  risk  over  time  are 
considered mitigation efforts. 
A fore running activity to the mitigation is the better identification 
of risks. Identifying and evaluating hazard is a physical process. In 
risk  assessment,  various  hazards  within  a  given  area  are 
identified.  Mitigation  measures  can  be  any  kind  structural  or 
nonstructural.  Structural  measures  use  technological  solutions 
while  non-structural  measures  include  legislation,  land  use 
planning  and  insurance.  Mitigation  is  the  most  cost  efficient 
process to reduce the impact or of hazards. However, mitigation is 
not  always  suitable  and  structural  mitigation  in  particular  may 
have  adverse  effects  on  ecosystem.  Mitigation  provides  the 
regulations  regarding  evacuations  and  sanctions  against  those 
who break the rules. If there is higher risk, then mitigation should 
be higher to slow down the severity, seriousness or painfulness.  
Preparedness 
An  efficient  preparedness  measure  is  to  create  an  Emergency 
Operations Center (EOC).  
Common preparedness measures include the following: 
  Communication plans having terminology and methods that 
can be understood easily. 
  Development and practice of multi-agency coordination and 
incident command. 
  Proper  maintenance  and  training  of  emergency  services, 
including  mass  human  resources  such  as  community 
emergency response teams. 
  Development and exercise of emergency population warning 
methods combined with emergency shelters and evacuation 
plans. 
  Inventory,  stockpiling  and  maintenance  of  supplies  and 
equipment. 
  Developing organizations of trained volunteers from amongst 
civilian  populations.  Professional  emergency  workers  are 
immediately  overwhelmed  in  mass  emergencies,  trained, 
organized  and  responsible  volunteers  can  be  extremely 
valuable.  Another  is  the  Red  Cross.  If  volunteers  are 
organized,  trained  in  the  incident  command  system,  and 
agree  to  mobilize,  it  may  go  a  long  way  in  the  mitigating 
hazards  as  has  been  demonstrated  by  experience  of 
Emergency Response Teams such as in the Red Cross etc, 
  Casualty  prediction  to  forecast  casualties  and  injuries  or 
deaths  arising  out  of  a  given  kind  of  event.  This  gives 
planners and administrators an idea of size and package of 
resources  needed  to  be  made  available  to  respond  to  a 
particular kind of event. 
Response & Recovery 
In the recovery phase, an attempt is made to restore the affected 
area to its original state. It differs from the response phase in its 
focus; recovery should be started as soon as possible after the 
emergency  needs  have  been  addressed.  Recovery  efforts  are 
primarily  concerned  with  actions  that  involve  reconstruction  of 
destroyed  property  may  be  some  reemployment  and  bring 
purchase  of  infrastructure.  An  important  aspect  of  effective 
recovery efforts is taking advantage of a ‘window of opportunity’ to 
take measures that might be otherwise unpopular. The citizens or 
public who has affected from the disaster are likely to accept the 
mitigation changes if the wound of disaster is still ripe. 
Preventing chemical disasters [7]
 
In  1987  the  global  chemical  industry  launched  a  voluntary 
initiative,  Responsible  Care,  committing  chemical  companies  to 
achieve  frequent  improvements  in  environmental,  health  and 
safety performance beyond or more levels of regulations required 
by the local or international regulations. 
The  chemical  industry,  in  countries  such  as  Japan,  Mexico, 
Canada,  China  and  Thailand  has  also  set  up  emergency 
networks.  Every  major  region  and  country  has  developed  and 
adapted  its  own  system,  following  ICE  and  CHEMTREC 
guidelines. 
Chemical  companies  are  complementing  emergency  networks 
with their own schemes and systems. Most chemical companies 
provide  their  deliveries  with  safety  data  sheets,  emergency 
procedures  and  emergency  labels,  under  the  supervision  of 
technical agencies. 
Companies  may  also  offer  direct  assistance  and  support  to 
disaster victims, by funding recovery activities, helping implement 
conservation  and  emergency  preparedness  plans,  and  offering 
medical  care  to  victims  and  their  families.  Experience  at  the 
organization and association has made us to formulate our own 
references on how great we can use international resources in the 
disaster  prevention  and  how  public-private  partnerships  may 
reduce impacts over the hazards. We must create a case or brief 
bag  of  disaster  reduction  actions  compiling  best  practice  and 
lessons  learned  from  previous  disasters,  and  an  archive  or 
classification of technologies for disaster reduction. The chemical 
industry should have well developed codes, translated into several 
other languages and adapt to the different environments in which 
we operate the organization. 
After  all  we  must  enroot,  establish  and  enhance  early  warning 
systems still the most severe aspect of risk reduction or attrition. 
We  need  to  create  suitable  technical  instruments,  constantly 
monitored and improved by network of professionals. The lack of 
suitable early-warning systems is the key obstacle to prevention, 
allowing accidents to develop into fully-fledged disasters. 
Risk management methods and tools are very important to 
find the risk and minimize its impact: [8, 9, 10]  
Basic risk management methods 
These  methods  involve  flowcharts,  previous  data,  cause  and 
effects diagrams. 
FMEA  (Failure  Mode  Effect  Analysis)  –  Potential  tool  for 
evaluation of processes failures and its impact on the product. It 
helps to find out important failures and its impact. It can be used 
for analysing the equipment or machines involved in process of 
manufacturing the product. 
FMECA (failure modes, effects, and critical analysis) – This model 
is helpful to find out the occurrence; degree of severity can be 
measured. It is helpful in finding out the risks and their impact in 
manufacturing process. 
Fault tree analysis This model shares the idea of tree or a chain 
which shows the failure (single failure) and reason for the failure Krishna et al                                                                                                               Mintage journal of Pharmaceutical & Medical Sciencesǀ1-4 
 
Vol 3 Issue 2, April– June 2014                                               www.mintagejournals.com                                                                                     4 
with one or more reasons involved for the cause of failure. It is 
helpful to find out the root cause of the failure. 
HACCP  (Hazard  analysis  critical  control  point)  –  This  is  a 
systematic,  proactive,  and  preventive  tool  for  assuring  product 
quality, reliability, and safety. It is a framed approach that employs 
technical  and  scientific  principles  to  analyze,  evaluate,  prevent, 
and  control  the  risks  and  cause  of  risks  from  manufacturing 
process, product and marketing. HACCP consists of the following 
seven steps: Determine the critical control points 
  Inculcate the critical limits 
  Authorize a team to monitor the critical control points. 
  Monitor and control is required when there is deviation. 
  Set up system to verify that the HACCP system is working 
effectively. 
  A  record-keeping  system  to  note  down  the  process  in 
employed. 
 
CONCLUSION  
Risk is present at every level in the industry and any type of the 
industry is associated with risk. The probability of uncertainty are 
may be high or low. Risks may be negative or positive (which are 
assumed as opportunities). Proper approach to manage the risk is 
very important and it cannot be done alone by a single individual. 
This  is  a  team  approach  and  followed  by  every  individual. 
Everyone  has  a  part  to  play  and  which  involves  assessing, 
evaluating,  and  implementing  the  strategies.  The  risk 
management is at the core of any organization. Risk management 
should be part of organization culture. Risk cannot be avoided but 
it can be turned to our advantage and make organization more 
resilient in coming future. As Pharma sector or industry is involved 
more in innovation, research and development the probability of 
uncertainty is very high and risk involved can cause huge loss of 
time, money, and efforts. Proper risk management methods and 
tools are required to assess and evaluate the risks. By evaluation, 
serious risks with severe impact can be found and solutions or 
measures  are  implemented  to  reduce  the  impact  of  risks.  The 
risks  measures  implemented  are  properly  monitored  and 
controlled so that to assure all things are going according to the 
plan.  The  risk  management  is  a  wise  investment  if  properly 
processed. 
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